A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase Beta
Clinical Trial Grant
Administered By
Pediatrics, Medical Genetics
Awarded By
Protalix LTD.
Start Date
June 18, 2018
End Date
January 31, 2021
Administered By
Pediatrics, Medical Genetics
Awarded By
Protalix LTD.
Start Date
June 18, 2018
End Date
January 31, 2021